Neurogene Reports $30.9 Million Net Loss in Q1 2026, Increases R&D Spending

Neurogene Inc. reported a net loss of $30.9 million for the first quarter of 2026, an increase from a net loss of $22.6 million during the same period in 2025. The company's total operating expenses rose to $33.3 million, compared to $25.9 million in the prior year, primarily driven by a significant increase in research and development costs, which reached $25.2 million, up from $17.8 million. This increase was largely attributed to heightened clinical trial expenses associated with the ongoing Phase 1/2 trial of NGN-401, a gene therapy for Rett syndrome, as well as increased costs related to chemistry, manufacturing, and controls (CMC).

In terms of financial position, Neurogene's total assets decreased to $263.1 million as of March 31, 2026, down from $288.6 million at the end of 2025. The decline in total assets was primarily due to a reduction in short-term investments, which fell from $165.2 million to $119.0 million. However, cash and cash equivalents increased to $124.2 million from $103.8 million, reflecting a net increase in cash flow from investing activities, which provided $46.2 million during the quarter, largely from the maturity of short-term investments.

Strategically, Neurogene has made significant advancements in its clinical programs, particularly with NGN-401, which is currently in a registrational trial known as the Embolden study. Approximately 90% of participants have been dosed, and the company is on track to complete dosing in the second quarter of 2026. The trial aims to evaluate the efficacy of NGN-401 in treating Rett syndrome, a severe neurodevelopmental disorder. The company has also received Breakthrough Therapy designation from the FDA for NGN-401, which is intended to expedite its development and review process.

Operationally, Neurogene has expanded its workforce, with an increase in employee headcount contributing to higher personnel-related expenses. The company continues to invest in its manufacturing capabilities, with a fully operational cGMP facility in Houston, Texas, which is expected to enhance product quality and development timelines. As of March 31, 2026, Neurogene had approximately 22.3 million shares outstanding, reflecting an increase in the weighted average shares due to stock options exercised and restricted stock units vested.

Looking ahead, Neurogene anticipates continued significant losses as it advances its clinical programs and builds its operational infrastructure. The company expects to rely on external capital to fund its operations, with cash reserves projected to be sufficient for at least the next year. Management has indicated that achieving profitability will depend on the successful development and commercialization of its product candidates, which may take several years. The company remains focused on its strategic goals while navigating the challenges inherent in the biotechnology sector.